Mind Medicine (MindMed) Inc. – NASDAQ:MNMD

Add to watchlist

$9.35

+2.51

+36.7%

Market open

Closed in about 5 hours

-8.31%

month

-8.31%

quarter

+80.47%

year

Market Cap	514.78M
Enterprise value	N/A

P/E	-1.7
EV/Sales	N/A
EV/EBITDA	0.94
Price/Sales	N/A
Price/Book	0.61
PEG ratio	-0.03
EPS	-2.94

Revenue	N/A
EBITDA	-91.84M
Income	-125.31M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Profit margin
Jun 2023	0	-29.13M
Sep 2023	0	-17.92M
Dec 2023	4.83M	-23.86M	-493.26%
Mar 2024	0	-54.4M

Mind Medicine (MindMed) Financials Estimate

Q Y

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Analyst Estimates
Dec 2023	4.83M	-23.86M	-493.26%
Mar 2024	0	-54.4M
Oct 2025	0	-18.42M
Dec 2025	0	-15.79M

Analysts Price target
Financials & Ratios estimates

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Debt to assets
Jun 2023	142085000	36.11M	25.42%
Sep 2023	141550000	45.57M	32.19%
Dec 2023	124541000	46.40M	37.26%
Mar 2024	275533000	79.47M	28.84%

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Cash Flow
Jun 2023	-13.84M	0	1.27M
Sep 2023	-16.62M	359K	17.39M
Dec 2023	-19.79M	-487.98K	2.31M
Mar 2024	-16.59M	0	169.24M

Mind Medicine (MindMed) alternative data

Mind Medicine (MindMed)
Employees

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Employee count
Aug 2023	48
Sep 2023	48
Oct 2023	48
Nov 2023	48
Dec 2023	48
Jan 2024	48
Feb 2024	48
Mar 2024	57
Apr 2024	57
May 2024	57
Jun 2024	57
Jul 2024	57

Mind Medicine (MindMed)
Hedge Funds Holdings Q3 2022

1.34% +0.97%

of MNMD is owned by hedge funds

55 -72

hedge funds hold MNMD stock

5.66M +4.13M

shares is hold by hedge funds

MNMD hedge funds holdings changes

Mind Medicine (MindMed)
Insider Trading

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	23097
Jun 2024	0	40438
Aug 2024	4500	0
Sep 2024	0	33424
Dec 2024	2500	32541

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	26 Dec 2024	BARROW ROBERT director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Shares	19,106	$7.43	$141,958
Sale	26 Dec 2024	LIAO CARRIE officer: Chief Accounting Officer officer: Chief Accounting Officer	Common Shares	2,273	$7.43	$16,888
Sale	26 Dec 2024	KARLIN DAN officer: Chief Medical Officer officer: Chief Medical Officer	Common Shares	6,643	$7.43	$49,357
Sale	26 Dec 2024	SULLIVAN MARK officer: Chief Legal Officer officer: Chief Legal Officer	Common Shares	4,519	$7.43	$33,576
Purchase	5 Dec 2024	GRYSKA DAVID W director director	Common Shares	2,500	$7.17	$17,925
Sale	25 Sep 2024	LIAO CARRIE officer: Chief Accounting Officer officer: Chief Accounting Officer	Common Shares	2,352	$5.98	$14,065
Sale	25 Sep 2024	BARROW ROBERT director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Shares	19,771	$5.98	$118,231
Sale	25 Sep 2024	KARLIN DAN officer: Chief Medical Officer officer: Chief Medical Officer	Common Shares	6,871	$5.98	$41,089
Sale	25 Sep 2024	SULLIVAN MARK officer: Chief Legal Officer officer: Chief Legal Officer	Common Shares	4,430	$5.98	$26,491
Purchase	23 Aug 2024	GRYSKA DAVID W director director	Common Shares	3,500	$5.98	$20,930

MNMD insider trading transactions

Mind Medicine (MindMed)
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q3 2023 2 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 3 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 5 May 2023	Q1 2023 Earnings Call Transcript

MNMD earnings call transcripts

Mind Medicine (MindMed)
Executives

Insider	Age	Since	Compensation
Mr. Stephen L. Hurst J.D. (1956) Co-Founder & Director	69		$420,830
Dr. Scott M. Freeman (1957) Co-Founder & Clinical Advisor	68		$337,190

Mind Medicine (MindMed)
Latest News

Tuesday, 24 December 2024
11:25	MindMed Stock Skyrockets 94% Year to Date: What's Driving It?	zacks.com
Monday, 23 December 2024
10:40	5 Biotech Breakthrough Stocks to Watch in 2025	zacks.com
Thursday, 19 December 2024
07:00	MindMed to Be Added to the Nasdaq Biotechnology Index	businesswire.com
Thursday, 5 December 2024
07:00	MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)	businesswire.com
Tuesday, 3 December 2024
07:00	MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy	businesswire.com
Monday, 2 December 2024
07:00	MindMed Announces New Employee Inducement Grants	businesswire.com
Sunday, 10 November 2024
09:55	Mind Medicine: No News = Good News	seekingalpha.com
Thursday, 7 November 2024
20:06	Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript	seekingalpha.com
Monday, 4 November 2024
16:04	Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate	seekingalpha.com
Thursday, 15 August 2024
12:30	Psychedelic Stocks: Focus On Their Cash	seekingalpha.com
Tuesday, 13 August 2024
11:21	Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript	seekingalpha.com
07:44	MindMed readying Phase III trials for LSD therapy to treat anxiety	marketwatch.com
07:01	Pacific Defense Announces US Army CMFF Program Team	businesswire.com
Monday, 12 August 2024
12:47	FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates	barrons.com
12:12	Psychedelic drug contender stocks drop after FDA rejects MDMA treatment	marketwatch.com
Friday, 9 August 2024
06:00	Mind Medicine (MindMed) Inc. Announces Proposed Public Offering	businesswire.com
Wednesday, 7 August 2024
14:29	MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy	seekingalpha.com
Saturday, 6 July 2024
07:21	3 Psychedelic Stocks to Ride to the Moon and Beyond	investorplace.com
Thursday, 4 July 2024
14:13	FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals	investorplace.com
Friday, 21 June 2024
07:00	MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	businesswire.com
Thursday, 20 June 2024
07:00	MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)	businesswire.com
Tuesday, 18 June 2024
12:31	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024	investorplace.com
Friday, 14 June 2024
10:40	Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?	zacks.com
Wednesday, 29 May 2024
10:46	Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?	zacks.com
Tuesday, 28 May 2024
07:00	MindMed to Participate in June Conferences	businesswire.com
Thursday, 23 May 2024
15:41	The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034	investorplace.com
12:15	Psychedelics Closer To Commercialization; Compass Far And Away The Leader	seekingalpha.com
Friday, 10 May 2024
11:00	Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May	InvestorPlace
Thursday, 9 May 2024
06:49	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine	InvestorPlace
Thursday, 25 April 2024
15:00	The Top 3 Small-Cap Stocks to Buy in April 2024	InvestorPlace

Ideas & Opinions

Seeking Alpha 10 Jun 2025

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Seeking Alpha 5 Jun 2024

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Seeking Alpha 4 Apr 2024

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Seeking Alpha 2 Feb 2024

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Seeking Alpha 13 Oct 2023

Mind Medicine: Q4 Of 2023 Data For GAD Makes This Worth A Look
Seeking Alpha 28 Jul 2022

The Growth Potential Of Psychedelics Stocks And ETFs
Seeking Alpha 27 May 2022

Atai Life Sciences And The Future Of Psychedelics For Mental Health
Seeking Alpha 27 Jan 2022

MindMed: Falling Uncontrollably
Seeking Alpha 23 Aug 2021

Mind Medicine: Short-Term Catalysts Fall Flat
Seeking Alpha 22 Aug 2021

MindMed: A Compelling Long-Term Buy In Biotech

Frequently Asked Questions (FAQ)

What's the price of Mind Medicine (MindMed) stock today?

One share of Mind Medicine (MindMed) stock can currently be purchased for approximately $9.35.
When is Mind Medicine (MindMed)'s next earnings date?

Unfortunately, Mind Medicine (MindMed)'s (MNMD) next earnings date is currently unknown.
Does Mind Medicine (MindMed) pay dividends?

No, Mind Medicine (MindMed) does not pay dividends.
How much money does Mind Medicine (MindMed) make?

Mind Medicine (MindMed) has a market capitalization of 514.78M.
What is Mind Medicine (MindMed)'s stock symbol?

Mind Medicine (MindMed) Inc. is traded on the NASDAQ under the ticker symbol "MNMD".
What is Mind Medicine (MindMed)'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Mind Medicine (MindMed)?

Shares of Mind Medicine (MindMed) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people:
- Mr. Stephen L. Hurst J.D. Co-Founder & Director(age: 69, pay: $420,830)
- Dr. Scott M. Freeman Co-Founder & Clinical Advisor(age: 68, pay: $337,190)
Is Mind Medicine (MindMed) founder-led company?

Yes, Mind Medicine (MindMed) is a company led by its founders Mr. Stephen L. Hurst J.D. and Dr. Scott M. Freeman.
How many employees does Mind Medicine (MindMed) have?

As Jul 2024, Mind Medicine (MindMed) employs 57 workers.
When Mind Medicine (MindMed) went public?

Mind Medicine (MindMed) Inc. is publicly traded company for more then 8 years since IPO on 15 Nov 2016.
What is Mind Medicine (MindMed)'s official website?

The official website for Mind Medicine (MindMed) is mindmed.co.
Where are Mind Medicine (MindMed)'s headquarters?

Mind Medicine (MindMed) is headquartered at 1055 West Hastings Street, Vancouver, BC.
How can i contact Mind Medicine (MindMed)?

Mind Medicine (MindMed)'s mailing address is 1055 West Hastings Street, Vancouver, BC and company can be reached via phone at +65 02082454.

Mind Medicine (MindMed) Inc.

mindmed.co

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

+65 02082454

1055 West Hastings Street
Vancouver, BC V6E 2E9

CIK: 0001813814
ISIN: CA60255C8850
CUSIP: 60255C109